Ligand Pharmaceuticals (LGND) Profit After Tax (QoQ) (2010 - 2026)
Ligand Pharmaceuticals (LGND) Profit After Tax (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Ligand Pharmaceuticals | 5.92 Bn | 5.14 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129.80% |
| Dec 31, 2025 | -61.81% |
| Sep 30, 2025 | 2,319.50% |
| Jun 30, 2025 | 111.42% |
| Mar 31, 2025 | -36.55% |
| Dec 31, 2024 | -333.46% |
| Sep 30, 2024 | 86.18% |
| Jun 30, 2024 | -160.26% |
| Mar 31, 2024 | 373.60% |
| Dec 31, 2023 | 277.05% |
| Sep 30, 2023 | -548.60% |
| Jun 30, 2023 | -94.54% |
| Mar 31, 2023 | 339.91% |
| Dec 31, 2022 | -4,427.97% |
| Sep 30, 2022 | 145.14% |
| Jun 30, 2022 | 94.18% |
| Mar 31, 2022 | -381.68% |
| Dec 31, 2021 | -123.27% |
| Sep 30, 2021 | -55.34% |
| Jun 30, 2021 | 34.95% |